

SEQUENCE LISTING

<110> Nihon Medi-Physics Co., Ltd.
 <120> Method for the production of radioactive metal-labeled antibodies
 <130> 093090
 <150> JP2019191561
 <151> 2019-10-18
 <160> 16
 <170> PatentIn version 3.5
 <210> 1
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Peptide for modifying antibody cited in the specification,
 paragraph [0109] (1)

<220>
 <221> SITE
 <222> (6)..(6)
 <223> Xaa is a lysine residue, a cysteine residue, an aspartic acid
 residue, a glutamic acid residue, a 2-aminosuberic acid or
 diaminopropionic acid.

<400> 1

Asp	Cys	Ala	Tyr	His	Xaa	Gly	Glu	Leu	Val	Trp	Cys	Thr
1				5					10			

<210> 2
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Peptide for modifying antibody cited in the specification,
 paragraph [0109] (2)

<220>
 <221> SITE
 <222> (8)..(8)
 <223> Xaa is a lysine residue, a cysteine residue, an aspartic acid
 residue, a glutamic acid residue, a 2-aminosuberic acid or
 diaminopropionic acid.

<400> 2

Gly	Pro	Asp	Cys	Ala	Tyr	His	Xaa	Gly	Glu	Leu	Val	Trp	Cys	Thr	Phe
1				5					10					15	

His



<210> 3
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide for modifying antibody cited in the specification,
paragraph [0109] (3)

<220>
<221> SITE
<222> (6)..(6)
<223> Xaa is a lysine residue, a cysteine residue, an aspartic acid
residue, a glutamic acid residue, a 2-aminosuberic acid or
diaminopropionic acid.

<400> 3

Arg Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Ser
1 5 10

<210> 4
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide for modifying antibody cited in the specification,
paragraph [0109] (4)

<220>
<221> SITE
<222> (8)..(8)
<223> Xaa is a lysine residue, a cysteine residue, an aspartic acid
residue, a glutamic acid residue, a 2-aminosuberic acid or
diaminopropionic acid.

<400> 4

Gly Pro Arg Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Ser Phe
1 5 10 15

His

<210> 5
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide for modifying antibody cited in the specification,
paragraph [0109] (5)

<220>
<221> SITE
<222> (8)..(8)
<223> Xaa is a lysine residue, a cysteine residue, an aspartic acid
residue, a glutamic acid residue, a 2-aminosuberic acid or



diaminopropionic acid.

<400> 5

Ser	Pro	Asp	Cys	Ala	Tyr	His	Xaa	Gly	Glu	Leu	Val	Trp	Cys	Thr	Phe
1				5					10					15	

His

<210> 6

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide for modifying antibody cited in the specification,
paragraph [0109] (6)

<220>

<221> SITE

<222> (8)..(8)

<223> Xaa is a lysine residue, a cysteine residue, an aspartic acid
residue, a glutamic acid residue, a 2-aminosuberic acid or
diaminopropionic acid.

<400> 6

Gly	Asp	Asp	Cys	Ala	Tyr	His	Xaa	Gly	Glu	Leu	Val	Trp	Cys	Thr	Phe
1				5					10					15	

His

<210> 7

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide for modifying antibody cited in the specification,
paragraph [0109] (7)

<220>

<221> SITE

<222> (8)..(8)

<223> Xaa is a lysine residue, a cysteine residue, an aspartic acid
residue, a glutamic acid residue, a 2-aminosuberic acid or
diaminopropionic acid.

<400> 7

Gly	Pro	Ser	Cys	Ala	Tyr	His	Xaa	Gly	Glu	Leu	Val	Trp	Cys	Thr	Phe
1				5					10					15	

His



<210> 8
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide for modifying antibody cited in the specification,
paragraph [0109] (8)

<220>
<221> SITE
<222> (8)..(8)
<223> Xaa is a lysine residue, a cysteine residue, an aspartic acid
residue, a glutamic acid residue, a 2-aminosuberic acid or
diaminopropionic acid.

<400> 8

Gly	Pro	Asp	Cys	Ala	Tyr	His	Xaa	Gly	Glu	Leu	Val	Trp	Cys	Ser	Phe
1				5					10					15	

His

<210> 9
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide for modifying antibody cited in the specification,
paragraph [0109] (9)

<220>
<221> SITE
<222> (8)..(8)
<223> Xaa is a lysine residue, a cysteine residue, an aspartic acid
residue, a glutamic acid residue, a 2-aminosuberic acid or
diaminopropionic acid.

<400> 9

Gly	Pro	Asp	Cys	Ala	Tyr	His	Xaa	Gly	Glu	Leu	Val	Trp	Cys	Thr	His
1				5					10					15	

His

<210> 10
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide for modifying antibody cited in the specification,
paragraph [0109] (10)



<220>
<221> SITE
<222> (8)..(8)
<223> Xaa is a lysine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, a 2-aminosuberic acid or diaminopropionic acid.

<400> 10

Gly Pro Asp Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Thr Phe
1 5 10 15

Tyr

<210> 11
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide for modifying antibody cited in the specification, paragraph [0109] (11)

<220>
<221> SITE
<222> (8)..(8)
<223> Xaa is a lysine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, a 2-aminosuberic acid or diaminopropionic acid.

<400> 11

Ser Pro Asp Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Thr Phe
1 5 10 15

Tyr

<210> 12
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide for modifying antibody cited in the specification, paragraph [0109] (12)

<220>
<221> SITE
<222> (8)..(8)
<223> Xaa is a lysine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, a 2-aminosuberic acid or diaminopropionic acid.

<400> 12

Ser Asp Asp Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Thr Phe
1 5 10 15



Tyr

<210> 13
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide for modifying antibody cited in the specification,
paragraph [0109] (13)

<220>
<221> SITE
<222> (8)..(8)
<223> Xaa is a lysine residue, a cysteine residue, an aspartic acid
residue, a glutamic acid residue, a 2-aminosuberic acid or
diaminopropionic acid.

<400> 13

Arg Gly Asn Cys Ala Tyr His Xaa Gly Gln Leu Val Trp Cys Thr Tyr
1 5 10 15

His

<210> 14
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide for modifying antibody cited in the specification,
paragraph [0109] (14)

<220>
<221> SITE
<222> (2)..(2)
<223> Xaa is a homosysteine residue.

<220>
<221> SITE
<222> (8)..(8)
<223> Xaa is a lysine residue, a cysteine residue, an aspartic acid
residue, a glutamic acid residue, a 2-aminosuberic acid or
diaminopropionic acid.

<220>
<221> SITE
<222> (16)..(16)
<223> Xaa is a homosysteine residue.

<400> 14

Gly Xaa Asp Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Thr Xaa
1 5 10 15



His

<210> 15
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide for modifying antibody cited in the specification, P3

<220>
<221> MOD_RES
<222> (1)..(1)
<223> linking to linker structure

<220>
<221> DISULFID
<222> (4)..(14)

<220>
<221> MOD_RES
<222> (8)..(8)
<223> modification with R1 structure

<400> 15

Gly	Pro	Asp	Cys	Ala	Tyr	His	Lys	Gly	Glu	Leu	Val	Trp	Cys	Thr	Phe
1				5					10					15	

His

<210> 16
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide for modifying antibody cited in the specification, P4

<220>
<221> MOD_RES
<222> (1)..(1)
<223> linking to linker structure

<220>
<221> MOD_RES
<222> (4)..(14)
<223> linking via linker structure

<220>
<221> MOD_RES
<222> (8)..(8)
<223> modification with R2 structure

<400> 16

Gly	Pro	Asp	Cys	Ala	Tyr	His	Lys	Gly	Glu	Leu	Val	Trp	Cys	Thr	Phe
1				5					10					15	



His

